Welcome to our dedicated page for MetaVia news (Ticker: MTVA), a resource for investors and traders seeking the latest updates and insights on MetaVia stock.
MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on cardiometabolic diseases, and its news flow centers on the development of two key product candidates: DA-1726 for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and vanoglipel (DA-1241) for MASH and type 2 diabetes. Company announcements frequently highlight clinical trial progress, new data readouts, and regulatory or listing updates that are relevant to investors and healthcare professionals following obesity and liver disease therapeutics.
News about DA-1726 includes Phase 1 multiple ascending dose results in obese but otherwise healthy adults, pharmacokinetic data supporting once-weekly subcutaneous dosing, and extended 8-week dosing cohorts at 48 mg. MetaVia has reported statistically significant weight loss, reductions in waist circumference, improvements in fasted glucose, and reductions in liver stiffness as measured by vibration-controlled transient elastography (VCTE), along with a favorable safety and tolerability profile. The company also releases updates on scientific presentations at meetings such as ObesityWeek, where DA-1726 data are shared with the medical community.
For vanoglipel (DA-1241), MetaVia’s news coverage includes Phase 2a trial results in presumed MASH patients, showing clinically meaningful reductions in glycated hemoglobin (HbA1c), improvements in liver inflammation and fibrosis markers, better liver steatosis and stiffness measures, and favorable shifts in plasma lipidomic profiles. The company announces poster presentations at major conferences such as the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, where detailed hepatic and metabolic data are presented.
In addition to clinical data, MetaVia issues news on corporate and capital market developments, including its 1-for-11 reverse stock split and communications regarding compliance with Nasdaq’s minimum bid price requirement. Readers of the MTVA news page can expect updates on trial milestones, conference presentations, research collaborations, and listing status, providing a consolidated view of MetaVia’s progress in cardiometabolic and liver disease drug development.
MetaVia (Nasdaq: MTVA), a clinical-stage biotechnology company specializing in cardiometabolic diseases, has announced its participation in the upcoming Emerging Growth Conference. The company's President and CEO Hyung Heon Kim, along with CFO Marshall H. Woodworth, will deliver a company update on December 4, 2024, at 4:10 pm ET.
The presentation will include a Q&A session, with attendees able to submit questions either in advance via email or during the event. Interested parties can register online to attend the virtual conference, with additional opportunities available for private management meetings.